KOD

Kodiak Sciences Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

52.40
+0.14
+0.27%
After Hours: 52.40 0 0.00% 16:00 09/23 EDT
OPEN
52.26
PREV CLOSE
52.26
HIGH
53.28
LOW
51.70
VOLUME
429.78K
TURNOVER
--
52 WEEK HIGH
82.75
52 WEEK LOW
13.39
MARKET CAP
2.34B
P/E (TTM)
-28.3412
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Kodiak Sciences to Present at Upcoming Conferences
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the following upcoming virtual investor conferences:
PR Newswire · 09/02 21:08
Kodiak Sciences EPS beats by $0.06
Kodiak Sciences (NASDAQ:KOD): Q2 GAAP EPS of -$0.58 beats by $0.06. Cash, cash equivalents and marketable securities of $417.13M. Press Release
seekingalpha · 08/10 14:38
Kodiak Sciences Announces Second Quarter 2020 Financial Results and Recent Business Highlights
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the sec
PR Newswire · 08/10 09:30
Top Small Cap Stocks for August 2020
Small cap stocks are listed companies that have market capitalizations typically ranging from $300 million to $2 billion. Since the share prices of these companies can have big fluctuations over a short period of time, companies with market caps of up to $10
Investopedia · 07/29 18:32
Kodiak Sciences (KOD) Presents At ASRS 38th Virtual Annual Meeting
Seeking Alpha · 07/24 21:38
Kodiak Sciences To Host R&D Webcast To Review Recent Data From Ongoing Phase 1b Study Of KSI-301 And Highlight KSI-301 Clinical Development Progress
PALO ALTO, Calif., July 16, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases,
Benzinga · 07/16 20:40
Kodiak Sciences to Host R&D Webcast to Review Recent Data from the Ongoing Phase 1b Study of KSI-301 and Highlight KSI-301 Clinical Development Progress
Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that it will host a R&D; Webcast for investors and analysts on Monday, July 27
PR Newswire · 07/16 20:38
Kodiak Sciences lead drug continues to show benefit in early-stage study in eye disorders
Seeking Alpha - Article · 07/10 20:18
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of KOD. Analyze the recent business situations of Kodiak Sciences Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average KOD stock price target is 82.56 with a high estimate of 115.00 and a low estimate of 52.00.
EPS
Institutional Holdings
Institutions: 151
Institutional Holdings: 39.88M
% Owned: 89.19%
Shares Outstanding: 44.71M
TypeInstitutionsShares
Increased
53
2.53M
New
38
269.29K
Decreased
26
1.14M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.24%
Pharmaceuticals & Medical Research
-1.27%
Key Executives
Chairman/President/Chief Executive Officer/Director
Victor Perlroth
Chief Financial Officer/Senior Vice President/Secretary/IR Contact Officer
John Borgeson
Other
Jason Ehrlich
Lead Director/Independent Director
Robert Profusek
Independent Director
Felix Baker
Independent Director
Charles Bancroft
Independent Director
Bassil Dahiyat
Independent Director
Richard Levy
Independent Director
Taiyin Yang
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About KOD
Kodiak Sciences Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapeutics to treat ophthalmic diseases. The Company’s Antibody Biopolymer Conjugate (ABC) platform focuses on merging the fields of antibody-based and chemistry-based therapies. The Company in addition to its lead product candidate, KSI-301, is a molecule for age-related macular degeneration and diabetic retinopathy. The Company has leveraged its ABC platform to build a pipeline of product candidates in various stages of development including KSI-501, a dual inhibitor ABC for the treatment of neovascular retinal diseases, such as wet AMD and diabetic retinopathy.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Kodiak Sciences Inc stock information, including NASDAQ:KOD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KOD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KOD stock methods without spending real money on the virtual paper trading platform.